Focused On-demand Library for Spliceosome-associated protein CWC27 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6UX04

UPID:

CWC27_HUMAN

Alternative names:

Antigen NY-CO-10; Probable inactive peptidyl-prolyl cis-trans isomerase CWC27 homolog; Serologically defined colon cancer antigen 10

Alternative UPACC:

Q6UX04; O60529; O60530; Q96EM3

Background:

Spliceosome-associated protein CWC27 homolog, also known as Antigen NY-CO-10 and Serologically defined colon cancer antigen 10, plays a crucial role in pre-mRNA splicing as part of the spliceosome. Despite its probable inactive PPIase status, it significantly contributes to the splicing of U12-type introns, underscoring its importance in RNA processing.

Therapeutic significance:

Linked to Retinitis pigmentosa with or without skeletal anomalies, a disease marked by retinal degeneration and neurologic defects, understanding the role of Spliceosome-associated protein CWC27 homolog could open doors to potential therapeutic strategies.